1. Introduction 

The Brain-Market Regulation Doctrine is a proposed legal and regulatory framework for governing commercial markets that involve the human brain, neural activity, brain-computer interfaces (BCIs), neural data, neurotechnology, and services that interpret or influence cognitive functions.

The term does not currently identify one universally recognized legal doctrine or a single established body of case law. It is better understood as an emerging interdisciplinary legal concept that draws on constitutional law, privacy and data-protection law, medical-device regulation, consumer protection, competition law, employment law, and bioethics.

The central proposition is that commercial activity involving the human brain must remain subject to human rights, informed consent, safety standards, fair competition, and effective legal accountability.

For example, imagine a company that sells a brain-computer interface capable of interpreting neural signals to control a computer. It collects brain-related data, licenses the technology to employers, and uses predictive software to infer workers' attention or fatigue. The Brain-Market Regulation Doctrine would ask:

Who may collect, analyze, license, or sell neural data?

What constitutes valid consent to the use of brain-related information?

Can employers or insurers make decisions based on neural inferences?

Who is liable if the technology causes physical injury, psychological harm, or unlawful discrimination?

How should regulators prevent monopolies over essential neurotechnology?

What remedies should be available when commercial interests conflict with individual autonomy?

These questions become especially important as neurotechnology moves from clinical treatment into workplaces, consumer products, education, insurance, and other commercial settings.

2. Objectives of the doctrine

The proposed doctrine can be organized around seven principal objectives.

1. Cognitive liberty and autonomy

Protect a person's ability to make decisions about access to their brain, neural stimulation, cognitive enhancement, and mental processes without coercion.

2. Neural privacy

Restrict unauthorized collection, inference, disclosure, reuse, and commercial exploitation of neural information.

3. Safety and clinical integrity

Require proportionate testing, risk management, monitoring, and incident reporting for neurotechnologies that affect health or bodily functions.

4. Market fairness

Prevent anticompetitive conduct, deceptive marketing, discriminatory pricing, and exploitation of users who depend on essential neurotechnology.

5. Protection against coercion

Safeguard workers, students, patients, and other individuals who may have limited practical ability to refuse neural monitoring.

6. Transparency and accountability

Require understandable explanations, independent audits, traceable decisions, and accessible complaint mechanisms.

7. Effective remedies

Enable compensation, injunctions, regulatory penalties, corrective action, and other appropriate remedies for violations.

3. Major legal principles

A. Human dignity and cognitive autonomy

The doctrine begins with the principle that the human brain must not be treated merely as a commercial resource. A person may agree to use a neural device, but that agreement does not necessarily authorize every subsequent use of the information collected by the device.

A sound regulatory framework should distinguish between:

Consent to use a device for medical treatment.

Consent to collect neural signals.

Consent to analyze or infer mental states.

Consent to transfer data to third parties.

Consent to use data for advertising, employment decisions, or commercial research.

These permissions should not be treated as interchangeable.

Legal significance: General contract law may be insufficient where consent is bundled into lengthy terms, refusal means losing essential services, or the individual cannot reasonably understand the consequences of neural-data processing.

B. Neural data as a protected category of information

Neural data can include recorded electrical activity, signals generated by brain-computer interfaces, and information inferred from those signals. Depending on the technology, it may reveal or suggest aspects of attention, movement intention, neurological conditions, or emotional states.

However, not every neural signal reliably reveals a person's thoughts. Legal safeguards must reflect the actual scientific capabilities and limitations of the technology.

A proposed regulation should address:

Data minimization and purpose limitation.

Encryption, access controls, and cybersecurity.

Restrictions on secondary use and commercial transfers.

Retention limits and deletion rights, subject to lawful exceptions.

Independent evaluation of systems that infer mental states.

Additional safeguards for children and individuals with reduced bargaining power.

In India, the constitutional right to privacy provides an important foundation for such protections. In the European Union, data-protection law and the AI Act provide complementary safeguards in their respective fields.

Indian Kanoon+1

C. Free and informed consent

Consent is meaningful only when a person has a genuine choice and understands the material consequences.

For example, a consumer purchasing a rehabilitation device should not automatically be treated as consenting to the manufacturer selling neural data to advertisers or insurers.

A proposed Brain-Market Regulation Doctrine would favor separate, specific permissions for materially different uses, together with withdrawal mechanisms where legally appropriate.

It would also recognize that formal consent may not be genuinely voluntary where a powerful employer, school, hospital, or insurer controls access to an important opportunity or service.

D. Product safety and medical responsibility

Brain-computer interfaces and other neurotechnologies may involve software errors, unsafe stimulation, incorrect interpretation of signals, cybersecurity vulnerabilities, or malfunctioning medical hardware.

A suitable regulatory system should allocate duties among manufacturers, software developers, clinicians, distributors, and operators according to their respective control over the risk.

Possible requirements include pre-market evaluation, clinical evidence where appropriate, incident reporting, software updates, post-market surveillance, and clear instructions concerning foreseeable misuse.

The applicable requirements depend on whether a product is a medical device, a general consumer product, an AI system, or a combination of these.

E. Fair competition and market access

Brain-related markets may become concentrated where a small number of companies control proprietary neural datasets, device interfaces, essential software, or access to specialized clinical services.

Competition-law concerns could include:

Exclusionary licensing agreements.

Refusal to provide interoperability without adequate justification.

Anticompetitive acquisitions of emerging neurotechnology firms.

Bundling essential hardware with proprietary software.

Exploitative or discriminatory commercial terms.

Misuse of privileged access to neural data to disadvantage competitors.

The doctrine would not require every company to share its intellectual property or data. Instead, it would seek to prevent unlawful exclusion while balancing privacy, cybersecurity, innovation, and legitimate intellectual-property rights.

4. Important case laws and their relevance

The following judgments do not establish a single doctrine called the Brain-Market Regulation Doctrine. Rather, they provide legal principles that could support its development.

Case 1. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1

Indian constitutional law

Court: Supreme Court of India, nine-judge bench
Decision date: 24 August 2017

Facts and legal issue: The Court considered whether the right to privacy is protected as a fundamental right under the Constitution of India.

Judgment: The Court unanimously recognized privacy as a fundamental right protected by the Constitution, including under Article 21 and the freedoms in Part III. The judgment established that privacy is connected with dignity, autonomy, and individual liberty.

Indian Kanoon+1

Application to brain-market regulation:

Neural information may warrant strong privacy protection when its collection or analysis intrudes into an individual's personal sphere.

State interference with protected privacy interests must satisfy constitutional requirements, including legality, a legitimate aim, and proportionality.

Government authorization alone does not make every form of neural surveillance constitutionally valid.

Example: If a public authority requires continuous neural monitoring of citizens without a sufficient legal basis or proportionate justification, the measure could be challenged under applicable constitutional principles.

Legal limitation: Puttaswamy did not specifically decide ownership of neural data or create a freestanding property right in brain signals. Its application to particular neurotechnologies requires further legal analysis.

Case 2. Selvi v. State of Karnataka, (2010) 7 SCC 263

Direct neurotechnology relevance

Court: Supreme Court of India
Decision date: 5 May 2010

Facts: The case concerned the involuntary administration of narcoanalysis, polygraph examinations, and Brain Electrical Activation Profile (BEAP) tests during criminal investigations.

Judgment: The Court held that involuntary administration of the impugned techniques violated Article 20(3)'s protection against compelled self-incrimination and infringed Article 21 protections relating to personal liberty. It distinguished voluntary testing and addressed the evidentiary treatment of information subsequently discovered.

Indian Kanoon+1

Application to brain-market regulation:

Brain-related examination cannot be justified merely because it may produce useful information.

The individual's freedom from coercive mental examination is a significant legal consideration.

Consent safeguards should account for legal advice, the circumstances of consent, and the nature of the examination.

Commercial neural testing should not be presumed permissible simply because a person has signed a general agreement.

Important distinction: Selvi concerned specific techniques used in criminal investigations. It does not automatically prohibit all voluntary brain-computer interfaces, neurological examinations, or therapeutic neurotechnology.

Nevertheless, it is one of the most directly relevant Indian precedents for a proposed doctrine concerned with the legal limits of extracting information from brain activity.

Case 3. Carpenter v. United States, 585 U.S. 296 (2018)

Court: Supreme Court of the United States
Decision date: 22 June 2018

Facts: Law enforcement obtained historical cell-site location records from wireless carriers without a warrant supported by probable cause.

Judgment: The Court held that obtaining the particular historical location records at issue constituted a Fourth Amendment search. It emphasized the unusually comprehensive and revealing nature of the digital records. The decision was narrow and did not eliminate the third-party doctrine in all contexts.

Supreme Court+1

Application to brain-market regulation:

Carpenter offers an analogy for evaluating sensitive information held by commercial intermediaries. The fact that a company possesses information does not necessarily settle every question about the individual's privacy interests or government access to it.

For neural data, the analogy is especially relevant where a service provider continuously collects highly personal signals that may reveal patterns of behavior or neurological activity.

Legal limitation: Carpenter concerns government access to location records under United States constitutional law. It does not directly establish that privately held neural data receives the same protection or that a company cannot commercially process such data.

Case 4. FTC v. Actavis, Inc., 570 U.S. 136 (2013)

Court: Supreme Court of the United States
Decision date: 17 June 2013

Legal principle: The Court held that certain pharmaceutical patent-settlement agreements involving substantial reverse payments could be examined under the rule of reason under antitrust law. Patent rights did not automatically immunize the challenged arrangements from competition-law scrutiny.

Application to brain-market regulation:

Suppose a neurotechnology manufacturer controls essential patented components and enters agreements that substantially restrict competing devices or delay competing products. Actavis illustrates the broader principle that intellectual-property rights and commercial agreements must be assessed alongside competition-law obligations.

The relevant inquiry would be whether the conduct violates the applicable antitrust rules, not whether the technology involves the brain.

Legal limitation: Actavis did not involve neurotechnology or neural data. Its relevance is analogical and depends on the facts and governing competition law.

Case 5. Carpenter v. United States and the broader third-party data problem

A separate lesson from Carpenter is that courts must examine the nature, scale, and sensitivity of information rather than assume that every record held by a private company is legally equivalent.

For brain-market regulation, this suggests distinguishing between ordinary device telemetry and data that could expose intimate neurological information. That distinction may support stricter safeguards, although the applicable legal rule must come from the relevant jurisdiction's legislation and precedents.

5. Additional legal authorities and regulatory frameworks

A. European Union AI Act

The EU AI Act, Regulation (EU) 2024/1689, provides an important example of risk-based regulation of technologies that infer human emotions or influence decisions.

Article 5(1)(f) prohibits specified AI systems used to infer emotions in workplaces and educational institutions, subject to exceptions including medical or safety purposes. The prohibition is not a general ban on all neural data processing or all neurotechnology.

EUR-Lex+1

Relevance: A brain-market regulator could similarly prohibit particularly intrusive or unreliable applications while permitting properly safeguarded medical and assistive uses.

B. UNESCO Recommendation on the Ethics of Neurotechnology

In November 2025, UNESCO adopted a global normative framework on neurotechnology ethics. It addresses the need to protect human rights, dignity, and the integrity of the human mind as neurotechnology advances.

UNESCO+1

Relevance: It offers an international policy foundation for national legislation. A UNESCO recommendation is not equivalent to a binding domestic statute or a judicial precedent; its legal effect depends on its character and subsequent implementation.

C. Competition-law principles

In the United States, antitrust principles prohibit unlawful monopolization and anticompetitive agreements, rather than simply prohibiting companies from becoming successful or acquiring large market shares.

Federal Trade Commission+1

In India, the Competition Act, 2002, provides the statutory framework for examining anticompetitive agreements, abuse of dominant position, and combinations. These provisions could apply to neurotechnology businesses where the relevant statutory requirements are met.

6. Application under Indian law

A proposed Brain-Market Regulation Doctrine would operate through existing Indian law, rather than replace it.

The exact obligations depend on the facts, applicable rules, commencement provisions, and relevant exemptions. In particular, neural information does not automatically fall outside or inside a particular statute merely because it originates from the brain.

7. Proposed regulatory model

A comprehensive regulatory framework could be designed around the following structure.

Six pillars of brain-market regulation

Registration and risk classification

Classify neurotechnology by intended use, invasiveness, potential harm, and the sensitivity of collected data.

Neural-data governance

Establish purpose restrictions, security requirements, retention rules, and controls on third-party access.

Consent and cognitive autonomy

Require meaningful consent, clear explanations, and safeguards against coercive or deceptive practices.

Independent safety and accuracy assessment

Evaluate clinical performance, security vulnerabilities, reliability of mental-state inferences, and discriminatory effects.

Market and employment safeguards

Scrutinize monopolistic conduct and restrict unjustified reliance on neural inferences in hiring, insurance, education, and other consequential decisions.

Enforcement and remedies

Provide independent oversight, complaints procedures, audits, proportionate penalties, compensation where legally justified, and judicial review.

Example of how the model would operate

Suppose a company markets a wearable neural device to improve employee productivity.

The company collects brain-related signals, generates attention scores, sells analytics to employers, and prevents competitors from accessing its proprietary interface.

Under the proposed framework, the legal assessment would proceed as follows:

Privacy: Determine what information is collected, what can reliably be inferred, and whether processing has a lawful basis.

Consent: Examine whether workers can genuinely refuse the monitoring without adverse consequences.

Accuracy: Determine whether the attention scores are scientifically valid for the claimed purpose.

Employment law: Assess whether the scores result in unlawful discrimination or other prohibited treatment.

Competition law: Investigate whether the interface restrictions unlawfully exclude competitors.

Liability: Identify whether the manufacturer, employer, or another participant breached an applicable legal duty and what remedies follow.

A violation would not automatically follow from the existence of neural monitoring. The outcome would depend on the evidence, the applicable law, and the proportionality of the practice.

8. Enforcement and liability

A complete framework should distinguish among several types of liability.

Civil liability: Compensation for injury, privacy violations, contractual breaches, or other actionable harm.

Regulatory liability: Administrative penalties, restrictions on marketing, corrective orders, or suspension of noncompliant operations where authorized.

Competition liability: Remedies for unlawful agreements, abuse of dominance, or prohibited mergers.

Criminal liability: Only where the conduct satisfies the elements of an applicable criminal offence.

Constitutional remedies: Judicial relief against unconstitutional state action, subject to the relevant legal requirements.

Responsibility should be allocated according to each actor's role. A device manufacturer, neural-data processor, healthcare provider, and employer may have different duties and defenses. Liability should not be imposed automatically merely because an entity participates in the brain-technology market.

9. Critical legal challenges

Several unresolved questions would need to be addressed before this proposed doctrine could become a coherent, independent legal framework.

First, scientific uncertainty. Neural signals do not always provide reliable evidence of thoughts, intentions, attention, or emotional states. Regulation should prevent misleading claims without treating all neural inferences as scientifically meaningless.

Second, ownership. It is unsettled whether neural data should primarily be governed through privacy rights, data-control rights, contractual protections, intellectual-property rules, or a combination of these. Treating the brain itself as ordinary commercial property would raise serious ethical and legal concerns.

Third, commercial innovation. Excessively broad restrictions could interfere with beneficial technologies for communication, rehabilitation, treatment, and accessibility.

Fourth, unequal bargaining power. A person may formally consent while having little practical choice because an employer, school, or healthcare provider requires the technology.

Fifth, cross-border enforcement. Neural data may be processed by device manufacturers, cloud providers, analytics firms, and healthcare organizations operating in different jurisdictions. Effective enforcement requires cooperation between relevant authorities.

10. Conclusion

The Brain-Market Regulation Doctrine is best understood as a proposed legal synthesis, not a settled doctrine already recognized by courts under that name.

Its strongest legal foundations are the constitutional protection of privacy and autonomy, safeguards against compelled mental examination, existing data-protection and consumer laws, medical-device regulation, and competition law. In India, K.S. Puttaswamy and Selvi provide particularly important judicial foundations, although neither establishes a comprehensive regime for commercial neural-data markets.

The ultimate objective is to allow beneficial neurotechnology to develop without turning the human brain into an unrestricted source of commercial extraction, coercive surveillance, or discriminatory decision-making.

For a deeper legal research project, the most useful next step would be to examine the Brain-Market Regulation Doctrine alongside the Brain-Market Governance Doctrine and Brain-Market Antitrust Regulation, distinguishing constitutional rights, regulatory duties, and competition-law remedies.